Business Wire

DEEPTECH-LABS

14.6.2022 09:02:09 CEST | Business Wire | Press release

Share
Europe’s Only Deeptech Demo Day: Deeptech Labs’ Unveil 6 New Accelerator Start-ups

Deeptech Labs , the accelerator and VC fund for post-Seed, pre-Series A deeptech companies will unveil its Spring cohort of 6 deeptech start-ups to an online audience of investors on 21st June. More than 120 VCs and Corporate Entities have previously attended its virtual demo days, demonstrating the significant and growing interest in the European deeptech sector.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220614005112/en/

Deeptech Labs is a Cambridge-based accelerator programme and VC fund, founded in 2020 by ARM, Cambridge Innovation Capital, Martlet Capital, Ewan Kirk and the University of Cambridge. The accelerator supports deeptech entrepreneurs as they move from prototype and proof of concept to scalable products and services, and connects them to Deeptech Labs’ extensive network of deeptech investors.

The Deeptech Labs accelerator programme and investment fund was founded to fill a significant gap in the European venture market and accelerate the growth of promising early-stage deeptech companies. Deeptech Labs supports its cohort companies through a specially-designed thirteen week accelerator programme, connecting founders with a global network of more than 50 world-leading deeptech entrepreneurs, technology experts and investors.

Watch Demo Day elevator pitches from the Spring ’22 cohort:

Anaphite (Bristol, UK) incorporates graphene into battery materials, to enable the creation of super-fast charge, long-range batteries - something that will have significant impact on the EV market.

  • Watch Anaphite’s 3-minute elevator pitch here

Toposens (Munich, Germany) is the world’s only 3D ultrasonic sensing technology for advanced collision avoidance. It uses echolocation and signal processing algorithms to make autonomous vehicles in the robotics and automotive industry smarter and safer.

  • Watch Toposens’ 3-minute elevator pitch here

SonicEdge (Shoham, Israel) has developed the world’s smallest speaker-in-chip that uses breakthrough ultrasound technology to completely transform the audio experience.

  • Watch SonicEdge’s 3-minute elevator pitch here

iKVA (Cambridge, UK) is an early-stage AI Knowledge Management company creating solutions for organisations to discover data and intelligently and proactively provide it to users when they need it, enabling better business insights.

  • Watch iKVA’s 3-minute elevator pitch here

Inovo Robotics (Guildford, UK) are democratising robotics with modular, no-code, low cost “cobots” that open up completely new opportunities for safe, flexible automation.

  • Watch Inovo Robotics’ 3-minute elevator pitch here

Nestwave (Paris, France) Nestwave provides advanced, IoT geolocation solutions to IoT modem and DSP vendors to significantly improve localization accuracy in critical indoor and dense urban environments while greatly reducing power consumption and solution footprint.

  • Watch Nestwave’s 3-minute elevator pitch here

Miles Kirby, CEO Deeptech Labs said, “Europe has a number of global advantages in deeptech – we have 50% of the world’s best universities and the highest number of highly cited research papers - but there’s a disparity when it comes to European investment in deeptech companies. European deeptech companies attract $33 billion compared to $144 billion in the US .

Thanks to our deeptech-specific accelerator programme, our cohort companies are stronger, more resilient and have highly focused go-to-market strategies and that’s why so many investors attend our Demo Days – and how we are helping to fix the European deeptech investment gap.”

  • Watch Miles’ 5 minute introduction to Deeptech Labs here .

Editors Notes

Deeptech Labs is an accelerator, VC fund, and the catalyst for deeptech success. Twice a year, its cohort of start-ups are embedded in a powerful network of successful entrepreneurs, expert practitioners, leading researchers, and deeptech organisations worldwide. Deeptech Labs is founded by ARM, Cambridge Innovation Capital, Martlet Capital, Ewan Kirk and the University of Cambridge - forefront institutions and individuals at the heart of the Cambridge and global technology ecosystems.

The company is headquartered in Cambridge, UK.

For more information, please visit dtl.vc

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Yubico Appoints Poupak Modirassari Enbom as Chief Marketing Officer to Accelerate Global Momentum and Drive Market Leadership30.3.2026 15:00:00 CEST | Press release

Yubico (NASDAQ STOCKHOLM: YUBICO), the creator of the most secure passkeys and a leading provider of hardware authentication security keys, today announced the appointment of Poupak Enbom as Chief Marketing Officer (CMO). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330278027/en/ Enbom joins Yubico at a pivotal moment as organizations worldwide accelerate the shift to phishing-resistant authentication and modern identity security in the age of AI. “We’re excited to welcome Poupak to Yubico,” said Jerrod Chong, acting chief executive officer, Yubico. “As the threat landscape evolves with AI-driven attacks and increasing automation, organizations are rethinking how they secure digital identities of both humans and AI agents at scale. She brings a unique combination of technical depth, global leadership, and customer-first mindset that will help us continue to expand our impact and support our customers and partners around

Westinghouse Celebrates Record-breaking 80 Years of Nuclear Fuel Manufacture at Springfields30.3.2026 14:00:00 CEST | Press release

Fuel manufactured at Springfields has generated enough energy to supply the UK’s electricity demand for 26 years, avoiding the emission of nearly 3 billion tonnes of CO2 The Westinghouse Springfields facility in Lancashire, UK, has marked a significant milestone as the oldest continuous nuclear fuel manufacturing site in the world, starting from its original license on the 28th, March 1946. The site was chosen by the UK Government to develop nuclear fuel for the world’s earliest civil nuclear power stations, as well as subsequent Magnox and Advanced Gas Reactors (AGR) reactors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330135973/en/ From left to right: Sophie Lemaire; Marc Chevrel; Rory O'Neill; Craig Boothby; and Robert Gofton, CEO at Nuclear Institute Across the last eight decades, the Springfields site has supported the UK nuclear fleet, manufacturing more than eight million AGR pins, sintering and pressing over 5

HistoSonics Treats First Patients Evaluating the Edison® Histotripsy System for the Treatment of Benign Prostatic Hyperplasia (BPH)30.3.2026 14:00:00 CEST | Press release

HistoSonics, the developer of the Edison® Histotripsy System and novel histotripsy therapy platform, today announced the successful treatments of the first patients in WOLVERINE, a prospective feasibility trial evaluating the Edison® Histotripsy System for the treatment of benign prostatic hyperplasia (BPH) at Prince of Wales Hospital in Hong Kong, a teaching hospital for The Chinese University of Hong Kong. The Edison System is a novel, non-invasive, image guided platform that uses the mechanical properties of focused ultrasound, called histotripsy, to destroy unwanted tissue without the need for invasive procedures, and with potentially fewer side effects than traditional, invasive therapies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330349844/en/ HistoSonics Non-Invasive Edison Histotripsy System. Image credit: HistoSonics WOLVERINE is a prospective, multi-center, single-arm feasibility trial designed to evaluate

Biocytogen Grants Taisho Pharmaceutical a License to its RenNano® Fully Human Heavy Chain-Only Antibody Discovery Platform30.3.2026 13:00:00 CEST | Press release

Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315), a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies, today announced that it has entered into a platform license agreement with Taisho Pharmaceutical Co., Ltd. (“Taisho”), granting Taisho the right to access and use Biocytogen’s proprietary RenNano® fully human heavy chain-only antibody (HCAbs) discovery platform for its internal research and development programs. Under the terms of the agreement, Taisho will leverage RenNano® mice to enable the generation and screening of fully human HCAbs in vivo and to support downstream research associated with antibody discovery. Financial terms of the agreement have not been disclosed. “We are very pleased to enter into this collaboration with Taisho,” said Dr. Yuelei Shen, President and CEO of Biocytogen. “RenNano® is a robust and powerful fully human VHH discovery platform that pro

Meiji Seika Pharma Invests in Centivax to Develop Next Generation Universal Vaccine Platform30.3.2026 13:00:00 CEST | Press release

Meiji Seika Pharma Co., Ltd. (Head Office: Chuo-ku, Tokyo, President and Representative Director: Toshiaki Nagasato) today announced a strategic investment in Centivax, Inc. (Head Office: South San Francisco, CA, USA), a biotechnology company developing next-generation vaccines and therapies for universal protection against highly diverse targets. Centivax’s lead program includes a universal seasonal influenza vaccine (Centi-Flu 01) currently in a Phase 1 clinical study. Unlike conventional seasonal flu vaccines, which must be manufactured annually based on recommended candidate vaccine viruses, Centivax’s platform focuses both antibody and cellular immune responses on conserved regions of the influenza virus that cannot mutate and are shared across strains and distant subtypes. This approach aims to generate broad, consistent, and durable immunity against both seasonal and pandemic influenza. Meiji’s strategic investment aims to accelerate the advancement of Centi-Flu 01 and further a

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye